文献速递腹部CTMRUS

超声造影对高危患者CT/MRI动脉期无高增强病灶(≥2 cm)的附加价值:聚焦CT/MRI LI-RADS LR-3与LR-4

Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4.
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

该前瞻性研究纳入43例高危患者共43个CT/MRI动脉期无高增强(APNHE)病灶(≥2 cm),行超声造影(CEUS)并按LI-RADS评估。CEUS使12个(27.9%)病灶呈现动脉期高增强,最终34个有明确诊断的病灶中CEUS额外诊断4例HCC和1例肝内胆管癌,但将1例良性病灶误诊为HCC。作者认为在CT/MRI APNHE病灶基础上加做CEUS有助于明确诊断HCC(CEUS LR-5)及其他恶性肿瘤(CEUS LR-M)。

要点

  • CT/MRI动脉期无高增强(LR-3/LR-4)病灶中,CEUS可使27.9%呈现动脉期高增强。
  • CEUS额外诊断了4例HCC(33.3%)和1例肝内胆管癌(100%)。
  • CEUS将1例良性病灶(4.5%)误诊为HCC。

核心结论

  • 在CT/MRI动脉期无高增强病灶基础上加做CEUS,有助于明确诊断HCC(CEUS LR-5)及其他恶性肿瘤(CEUS LR-M)。

研究设计与样本

  • 前瞻性研究,经IRB批准,纳入43例高危患者共43个CT/MRI动脉期无高增强(≥2 cm)病灶,均行CEUS并按LI-RADS评估;平均随访11.8±2.1个月;参考标准基于34个病灶,其中活检2例、手术2例、随访影像30例。

关键影像表现/征象

  • 43个APNHE病灶中12个(27.9%)在CEUS上呈现动脉期高增强,伴早期廓清1个(CEUS LR-M)、晚期廓清10个(CEUS LR-5)、无廓清1个(CEUS LR-4)。
  • CEUS与CT增强模式一致者动脉期16个(44.4%)、门静脉期20个(55.6%)。
  • CEUS与MRI增强模式一致者动脉期13个(59.1%)、门静脉期14个(63.6%)。

诊断标准与关键数值

  • 34个有最终诊断的APNHE病灶中,HCC 12个、肝内胆管癌1个、非恶性21个。
  • CEUS额外诊断HCC 4个(33.3%)和肝内胆管癌1个(100%)。
  • CEUS将1个非恶性病灶(4.5%)误诊为HCC。

临床应用与阅片要点

  • 对CT/MRI动脉期无高增强的LR-3/LR-4病灶,加做CEUS可帮助明确HCC(CEUS LR-5)或其他恶性肿瘤(CEUS LR-M)。
  • CEUS与CT/MRI的LI-RADS动态特征可不一致,可能反映两种造影剂特性不同,两系统不可互换。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the added value of CEUS on arterial phase non-hyperenhancement (APNHE) observations (LR-3 and LR-4) of CT/MRI in high-risk patients.

METHODS: Forty-three patients with APNHE observations (≥ 2 cm) from CT/MRI were prospectively enrolled in this IRB-approved study and underwent CEUS. All observations were assessed by LI-RADS for CT/MRI and CEUS. The hemodynamic findings were compared. The mean follow-up period was 11.8 ± 2.1 months. Reference standard was made on 34-APNHE observations based on biopsy (n = 2), surgery (n = 2), and follow-up image (n = 30).

RESULTS: The median of observation size was 2.3 cm (IQR 2.0-2.5 cm). Among the 43-APNHE observations, 12-observations (27.9%) were further presented as arterial phase hyperenhancement (APHE) in CEUS with early (n = 1, CEUS LR-M), late (n = 10, CEUS LR-5), or no (n = 1, CEUS LR-4) washout. Compared to CT, CEUS presented concordant enhancement patterns in 16 (44.4%) in AP and 20 (55.6%) in PVP, respectively. Similarly, 13 (59.1%) and 14 (63.6%) observations showed concordant enhancement patterns between CEUS and MRI in AP and PVP, respectively. Of the 34-APNHE observations with final diagnosis (hepatocellular carcinoma [HCC] n = 12; intrahepatic cholangiocarcinoma [IHCC], n = 1; non-malignancy, n = 21), 4 HCCs (33.3%) and 1 IHCC (100%) were additionally diagnosed by CEUS, while 1 non-malignant lesion (4.5%) was misdiagnosed as HCC by CEUS.

CONCLUSION: Adding CEUS to APNHE observations from CT/MRI would be useful not only for definitely diagnosing HCC (CEUS LR-5) but also for other malignancies (CEUS LR-M). The discordance of dynamic features between the LI-RADS for CEUS and CT/MRI may reflect the different properties of contrast media, although the systems are not interchangeable.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Kang HJ, Kim JH, Joo I, et al. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4. Abdom Radiol (NY). 2020. PMID: 31332503. doi:10.1007/s00261-019-02132-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。